TOP PAGE
ENGLISH
JAPANESE
|
CONNECT WITH US:
Home
About
Services
Contact
Log in
Home
Press release
Oct 04, 2022 16:44 JST
Source:
Eisai
Eisai Completes Construction of Its New Injection/Research Building at Kawashima Industrial Park in Japan
To Strengthen its Research and Development Function for Injectable Drug Formulations
TOKYO, Oct 04, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced that, as part of the strategic investment towards the realization of its medium-term business plan "EWAY Future & Beyond", it has completed construction of the new injection/research building "Eisai Medicine Innovation Technology Solutions" ("EMITS") at the Kawashima Industrial Park located in Gifu Prefecture, Japan.
External view of EMITS
EMITS will be Eisai's global base for formulation and modality research. In recent years, Eisai's drug discovery targets have expanded to include modalities such as antibodies, antibody drug conjugates (ADCs), and nucleic acid drugs, in addition to conventional small molecule compounds. At EMITS, Eisai will strengthen its injectable drug formulation development research function and drug delivery system (DDS) development function, including liposomal and lipid nanoparticle formulations, and address the development of various modalities. The following initiatives will be implemented.
- Elevating the quality and speed of formulation process research through introduction of a state-of-the-art manufacturing data management system and utilization of AI
- Installation of facilities that also enable the manufacturing of clinical trial materials in order to manufacture investigational injection drugs in-house
- Introduction of rapid microbial testing methods for advanced microbiological control and sterility assurance
- Enhancing collaboration with the creation of flexible space that can also be used for collaborative research with external partners and technologies
Through these efforts, Eisai aims to elevate the quality of the technology and knowledge of its formulation research function, and to become a base for disseminating innovation, technology, and solutions relating to formulations. The aggregate investment in the construction of EMITS is approximately 10 billion Japanese yen.
The Kawashima Industrial Park is Eisai's global pharmaceutical manufacturing base, at which Eisai has made a comprehensive framework comprising all steps from formulation research to formulation manufacturing. Through the construction of EMITS, Eisai aims to elevate the quality of its formulation research and formulation manufacturing, accelerate medicine creation activities, and ultimately further its contribution to improving the benefits of patients and their families.
Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120
For more information, visit www.eisai.com/news/2022/news202273.html.
Source: Eisai
Sectors: BioTech
Copyright ©2023 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Related Press Release
LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Demonstrates Long-Term, Durable Survival Benefit Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma
May 26 2023 13:15 JST
Eisai's Initiatives for Developing New Medicines for Neglected Tropical Diseases and Malaria
May 25 2023 20:02 JST
Eisai Delivers New Data and Highlights Continued Progress of Oncology Portfolio and Pipeline at ASCO 2023
May 24 2023 17:03 JST
Eisai Submits Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease in Great Britain
May 20 2023 09:20 JST
Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer's Disease
May 16 2023 08:27 JST
Eisai Enters Into Joint Development Agreement with Blissbio for Antibody Drug Conjugate BB-1701 with Option Rights for Strategic Collaboration
May 08 2023 10:15 JST
Eisai Completes a Major Renovation of Tsukuba Research Laboratories
April 06 2023 17:32 JST
Eisai Publishes Long-Term Health Outcomes Using Simulation Model of Lecanemab Using Phase 3 Clarity Ad Data in Peer-Reviewed Neurology and Therapy Journal
April 04 2023 12:23 JST
Eisai Enters Into Agreement With National Cancer Center to Collaborate on Investigator-Initiated Clinical Research for Anticancer Agent Tazemetostat Based on "Patient-Proposed Healthcare Services" System
April 03 2023 12:06 JST
Eisai Presented New Analyses of Aria and QOL on Lecanemab in Clarity AD at the AD/PD 2023 Annual Meeting
March 31 2023 15:51 JST
More Press release >>
Latest Press Release
Olympus Names Wenlei Yang the Newly Established Chief Diversity, Equity and Inclusion Officer
May 29, 2023 15:00 JST
Olympus Names Wenlei Yang the Newly Established Chief Diversity, Equity and Inclusion Officer
May 29, 2023 15:00 JST
Toyota: Development and Verification of Stationary Storage Battery System Using Electric Vehicle Storage Batteries
May 29, 2023 13:31 JST
Mitsubishi Electric and Mitsubishi Heavy Industries Definitively Agree to Integrate Their Power-generator Systems Businesses
May 29, 2023 11:24 JST
Liquid Hydrogen-Powered Corolla to Participate in the Super Taikyu Fuji 24 Hours Race
May 29, 2023 09:08 JST
Imposing island challenge awaits TOYOTA GAZOO Racing
May 26, 2023 17:35 JST
Results of a Collision Test Conducted on the Driver's Side of a Toyota RAIZE
May 26, 2023 15:07 JST
LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Demonstrates Long-Term, Durable Survival Benefit Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma
May 26, 2023 14:15 JST
'Fujitsu Technology and Service Vision 2023': sustainability and business converge to solve society's challenges
May 26, 2023 10:12 JST
Eisai's Initiatives for Developing New Medicines for Neglected Tropical Diseases and Malaria
May 25, 2023 21:02 JST
TOYOTA GAZOO Racing Opens Le Mans 24 Hours Special Website
May 25, 2023 18:28 JST
Hitachi Enhances Diversity, Equity and Inclusion by Supporting LGBTQIA+ Community
May 25, 2023 18:22 JST
Hitachi: Commencement of Joint Studies on Business Initiatives Towards the Development of Sustainable Finance
May 25, 2023 16:10 JST
MHI Thermal Systems to Release Fully Revamped 3HP Model in "HyperInverter" Series of Packaged Air-Conditioners for Domestic Market
May 25, 2023 12:02 JST
SumUp partners with JCB to boost card acceptance for European merchants within its 4-million-strong global network
May 25, 2023 12:00 JST
Mazda 787B to Demonstrate at 24 Hours of Le Mans Centenary Anniversary
May 25, 2023 10:43 JST
Honda to Participate in FIA Formula One World Championship from 2026 Season as Power Unit Supplier for Aston Martin Aramco Cognizant Formula One Team
May 24, 2023 19:01 JST
Eisai Delivers New Data and Highlights Continued Progress of Oncology Portfolio and Pipeline at ASCO 2023
May 24, 2023 18:03 JST
Mitsubishi Power to Develop Hydrogen-Ready Power Plant for Sembcorp Industries
May 24, 2023 16:06 JST
Mitsubishi Shipbuilding Completes Delivery of Ammonia Fuel Supply System for Large, Low-Speed Two Stroke Marine Engines
May 24, 2023 09:41 JST
More Latest Release >>